A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Janssen Research & Development, LLC
Hackensack Meridian Health
University Hospital, Caen
Memorial Sloan Kettering Cancer Center
Gilead Sciences
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
European Myeloma Network B.V.
First Affiliated Hospital of Zhejiang University
Merck Sharp & Dohme LLC
Celgene
Hoffmann-La Roche
Dartmouth-Hitchcock Medical Center
Takara Bio Inc.
Astellas Pharma Inc
Delta-Fly Pharma, Inc.